Comparing Moderna’s mRNA-1083 and Pfizer’s dual-target mRNA vaccines for influenza and COVID-19
Abstract This review examines Moderna’s mRNA-1083 and Pfizer/BioNTech’s mRNA-1020/1030 dual-target vaccines for COVID-19 and influenza. Both utilize mRNA technology, demonstrating strong immunogenicity and favorable safety profiles. Moderna’s mRNA-1083 showed superior immune responses, while Pfizer’...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-025-01145-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849326035091324928 |
|---|---|
| author | Adewunmi Akingbola Abiodun Adegbesan Kolade Adegoke Courage Idahor Petra Mariaria Favour Peters Raolat Adenike Salami Olajide Ojo Emmanuel Nwaeze Owolabi Abdullahi Joel Chuku |
| author_facet | Adewunmi Akingbola Abiodun Adegbesan Kolade Adegoke Courage Idahor Petra Mariaria Favour Peters Raolat Adenike Salami Olajide Ojo Emmanuel Nwaeze Owolabi Abdullahi Joel Chuku |
| author_sort | Adewunmi Akingbola |
| collection | DOAJ |
| description | Abstract This review examines Moderna’s mRNA-1083 and Pfizer/BioNTech’s mRNA-1020/1030 dual-target vaccines for COVID-19 and influenza. Both utilize mRNA technology, demonstrating strong immunogenicity and favorable safety profiles. Moderna’s mRNA-1083 showed superior immune responses, while Pfizer’s mRNA-1020/1030 performed well but was slightly less effective against influenza B. These vaccines simplify immunization strategies, enhance protection, and emphasize the need for global vaccine equity to prevent future outbreaks. |
| format | Article |
| id | doaj-art-291e98f50a2d438c81d146bea515fdbc |
| institution | Kabale University |
| issn | 2059-0105 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj-art-291e98f50a2d438c81d146bea515fdbc2025-08-20T03:48:15ZengNature Portfolionpj Vaccines2059-01052025-05-0110111010.1038/s41541-025-01145-6Comparing Moderna’s mRNA-1083 and Pfizer’s dual-target mRNA vaccines for influenza and COVID-19Adewunmi Akingbola0Abiodun Adegbesan1Kolade Adegoke2Courage Idahor3Petra Mariaria4Favour Peters5Raolat Adenike Salami6Olajide Ojo7Emmanuel Nwaeze8Owolabi Abdullahi9Joel Chuku10Department of Public Health and Primary Care, University of Cambridge Old Schools Trinity Lane CB2 1TN Cambridgeshire EnglandAfrican Cancer Institute, Department of Global Health, Stellenbosch UniversityFaculty of Clinical Sciences, Obafemi Awolowo UniversityNottingham University Hospitals NHS TrustDepartment of Public Health and Primary Care, University of Cambridge Old Schools Trinity Lane CB2 1TN Cambridgeshire EnglandDepartment of Public Health and Primary Care, University of Cambridge Old Schools Trinity Lane CB2 1TN Cambridgeshire EnglandAfe Babalola UniversityUniversity of West England, Coldharbour Ln, Stoke GiffordDepartment of community Health, Lagos State University College of MedicineDepartment of Medicine, Faculty of Clinical Sciences, Bayero UniversityDepartment of Medicine, V.N Karazin Kharkiv National University, Svobody SquareAbstract This review examines Moderna’s mRNA-1083 and Pfizer/BioNTech’s mRNA-1020/1030 dual-target vaccines for COVID-19 and influenza. Both utilize mRNA technology, demonstrating strong immunogenicity and favorable safety profiles. Moderna’s mRNA-1083 showed superior immune responses, while Pfizer’s mRNA-1020/1030 performed well but was slightly less effective against influenza B. These vaccines simplify immunization strategies, enhance protection, and emphasize the need for global vaccine equity to prevent future outbreaks.https://doi.org/10.1038/s41541-025-01145-6 |
| spellingShingle | Adewunmi Akingbola Abiodun Adegbesan Kolade Adegoke Courage Idahor Petra Mariaria Favour Peters Raolat Adenike Salami Olajide Ojo Emmanuel Nwaeze Owolabi Abdullahi Joel Chuku Comparing Moderna’s mRNA-1083 and Pfizer’s dual-target mRNA vaccines for influenza and COVID-19 npj Vaccines |
| title | Comparing Moderna’s mRNA-1083 and Pfizer’s dual-target mRNA vaccines for influenza and COVID-19 |
| title_full | Comparing Moderna’s mRNA-1083 and Pfizer’s dual-target mRNA vaccines for influenza and COVID-19 |
| title_fullStr | Comparing Moderna’s mRNA-1083 and Pfizer’s dual-target mRNA vaccines for influenza and COVID-19 |
| title_full_unstemmed | Comparing Moderna’s mRNA-1083 and Pfizer’s dual-target mRNA vaccines for influenza and COVID-19 |
| title_short | Comparing Moderna’s mRNA-1083 and Pfizer’s dual-target mRNA vaccines for influenza and COVID-19 |
| title_sort | comparing moderna s mrna 1083 and pfizer s dual target mrna vaccines for influenza and covid 19 |
| url | https://doi.org/10.1038/s41541-025-01145-6 |
| work_keys_str_mv | AT adewunmiakingbola comparingmodernasmrna1083andpfizersdualtargetmrnavaccinesforinfluenzaandcovid19 AT abiodunadegbesan comparingmodernasmrna1083andpfizersdualtargetmrnavaccinesforinfluenzaandcovid19 AT koladeadegoke comparingmodernasmrna1083andpfizersdualtargetmrnavaccinesforinfluenzaandcovid19 AT courageidahor comparingmodernasmrna1083andpfizersdualtargetmrnavaccinesforinfluenzaandcovid19 AT petramariaria comparingmodernasmrna1083andpfizersdualtargetmrnavaccinesforinfluenzaandcovid19 AT favourpeters comparingmodernasmrna1083andpfizersdualtargetmrnavaccinesforinfluenzaandcovid19 AT raolatadenikesalami comparingmodernasmrna1083andpfizersdualtargetmrnavaccinesforinfluenzaandcovid19 AT olajideojo comparingmodernasmrna1083andpfizersdualtargetmrnavaccinesforinfluenzaandcovid19 AT emmanuelnwaeze comparingmodernasmrna1083andpfizersdualtargetmrnavaccinesforinfluenzaandcovid19 AT owolabiabdullahi comparingmodernasmrna1083andpfizersdualtargetmrnavaccinesforinfluenzaandcovid19 AT joelchuku comparingmodernasmrna1083andpfizersdualtargetmrnavaccinesforinfluenzaandcovid19 |